Document:

EX-10.1

 Exhibit 10.1 

TERMINATION AND FEE AGREEMENT 

This TERMINATION AND FEE AGREEMENT (this “Agreement”), dated as of March 11, 2022, is made and entered into by and among
VPC Impact Acquisition Holdings II, an exempted company incorporated in the Cayman Islands with limited liability (“VIH”), AG1 Holdings, Ltd., an exempted company incorporated in the Cayman Islands with limited liability
(“Holdco”), AG2 Holdings, Ltd., an exempted company incorporated in the Cayman Islands with limited liability (“Merger Sub”), FinAccel Pte. Ltd., a Singapore private company limited by shares (the “Target
Company”) and Akshay Garg in his capacity as the Shareholders Representative (the “Shareholders Representative”) pursuant to Section 13.18 of the Business Combination Agreement (as defined below) (each, a
“Party” and collectively, the “Parties”). 
 RECITALS 

WHEREAS, on August 2, 2021, VIH, Holdco, Merger Sub, Target Company, the Shareholders and the Shareholders Representative entered into
that certain Business Combination Agreement, as amended by that certain First Amendment to Business Combination Agreement dated September 29, 2021 (as amended, restated or otherwise modified, the “Business Combination
Agreement”); 
 WHEREAS, pursuant to Section 12.01(a) of the Business Combination Agreement, the Business Combination
Agreement may be terminated by the mutual written consent of the Target Company and VIH; and 
 WHEREAS, the Parties desire to execute this
Agreement in order to mutually terminate the Business Combination Agreement on the terms set forth herein, effective as of the date hereof (the “Termination Date”), pursuant to Section 12.01(a) of the Business Combination
Agreement. 
 AGREEMENT 

NOW, THEREFORE, in consideration of the mutual agreements, covenants and other promises set forth herein, the mutual benefits to be gained by
the performance thereof, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged and accepted, and intending to be legally bound, the Parties hereto hereby agree as follows: 

ARTICLE I 
 DEFINITIONS

 Section 1.1. Definitions. 

(a) Unless otherwise specifically defined herein, each capitalized term used but not defined herein shall have the meaning assigned to such
term in the Business Combination Agreement. 
 (b) For purposes of this Agreement, the following terms shall have the following meanings:

 (i) “Claims” shall mean all claims, contentions, rights, debts, liabilities, demands, accounts,
reckonings, obligations, duties, promises, costs, expenses (including, without limitation, attorneys’ fees and costs), liens, damages, losses, actions, complaints, controversies, suits, proceedings, judgments, orders, and causes of action, of
any kind whatsoever, whether due or owing in the past, present or future and whether based upon contract, tort, statute or any other legal or equitable theory of recovery, and whether known or unknown, suspected or unsuspected, asserted or
unasserted, fixed or contingent, matured or unmatured. 

 (ii) “VPC Financing Agreements” shall mean (i) that
certain Senior Note Issuance Agreement, dated as of July 10, 2020, by and among the Target Company, as the sponsor, LimeRock Limited, as the company, PT FinAccel Finance Indonesia, as the servicer and an operator, PT FinAccel Digital Indonesia,
as an operator, Victory Park Management, LLC, as the registrar and agent, and PT Bank CIMB Niaga Tbk, as the security trustee (as amended, amended and restated, supplemented, novated and/or otherwise modified from time to time, including, without
limitation, by that certain Amendment and Restatement Agreement, dated as of November 9, 2020, that certain Second Amendment and Restatement Agreement, dated as of June 8, 2021, that certain Third Amendment and Restatement Agreement, dated
as of November 4, 2021, and that certain Fourth Amendment and Restatement Agreement, dated as of March 11, 2022, collectively, the “Senior Loan Note Issuance Agreement”), including any and all other agreements, documents,
certificates and instruments contemplated thereby or incidental or related thereto (including, without limitation, all other agreements, documents, certificates and instruments defined as “Finance Documents” in the Master Definitions and
Construction Schedule (as defined in the Senior Loan Note Issuance Agreement)), in each case, as may be further amended, amended and restated, supplemented, novated and/or otherwise modified from time to time; and (ii) those certain Convertible
Promissory Notes, dated as of March 11, 2022, held by Victory Park Capital Advisors, LLC, Corbin Capital Partners, L.P., and/or any of their respective Affiliates (the “Convertible Promissory Notes”), including those certain Warrants,
dated as of March 11, 2022, issued by the Target Company to Victory Park Capital Advisors, LLC, Corbin Capital Partners, L.P., and/or their respective Affiliates in connection with such Convertible Promissory Notes, in each case, as may be
amended, amended and restated, supplemented, novated and/or otherwise modified from time to time. 
 ARTICLE II 

TERMINATION OF THE BUSINESS COMBINATION AGREEMENT 

Section 2.1. Termination; Effect of Termination on the Business Combination Agreement. The Business Combination Agreement is
hereby terminated, effective as of the Termination Date (the “Business Combination Agreement Termination”), in accordance with Article XII of the Business Combination Agreement and the Parties’ rights and obligations under the
Business Combination Agreement are those set forth in Section 12.02 of the Business Combination Agreement. The Parties hereto acknowledge that, by virtue of the Business Combination Agreement Termination, the Subscription Agreements and all
other Ancillary Documents (other than the Confidentiality Agreement) shall also terminate in accordance with their terms on the Termination Date. 

ARTICLE III 
 FEES

 Section 3.1. Payments. 

(a) As a reimbursement of certain expenses, costs and other losses incurred by VIH and/or VPC Impact Acquisition Holdings Sponsor II, LLC, a
Delaware limited liability company (the “VIH Sponsor”), in connection with the Business Combination Agreement, the Ancillary Documents and all other matters related to the transactions contemplated by the Business Combination
Agreement and the Ancillary Documents, and in consideration of the representations, warranties, covenants and agreements contained herein, the Target Company shall pay (and/or shall issue and deliver, as the case may be) when due the amounts
described in this Section 3.1 as set forth below: 
 (i) Within six (6) months of the date of
the execution of this Agreement, the Target Company shall pay VIH an aggregate sum not to exceed $4,000,000 (the “Termination Reimbursement Amount”), in reimbursement of certain documented out-of-pocket third party expenses incurred by VIH, by wire transfer of immediately available funds to the account set forth in Annex A; and 

  
 2 

 (ii) if VIH provides written notice (including via email) to the Target
Company that VIH (x) has not consummated an initial business combination and (y) has determined to redeem its public shares and liquidate or dissolve thereafter (and does not withdraw such determination) (such liquidation, a “VIH
Liquidation”), the Target Company shall issue and deliver to VIH, a penny warrant (the “Warrant”), which shall contain customary protections for the warrantholder and otherwise reflect terms mutually agreeable to the Target
Company and VIH to be negotiated in good faith, to purchase a number of Target Company Ordinary Shares equal to three and one-half percent (3.5%) of the Fully Diluted Share Number as of the date of this
Agreement (as adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Target Company Ordinary Shares on or after the date hereof and on or prior to the date of the Warrant is exercised);
provided that, for sake of clarity, such adjustments shall not be duplicative of any adjustments pursuant to the provisions of the Warrant (the “Equity Termination Fee”); provided, further that the Warrant (and
any shares of Target Company Ordinary Shares issuable upon the exercise thereof) shall be non-transferable (subject to limited exceptions contained therein) and shall be issued solely to VIH within five
(5) Business Days following and conditional upon both of the following to occur: (i) the dissolution of the Trust Account and (ii) the distribution of the cash proceeds held therein to holders of Class A ordinary shares of a par
value of $0.0001 of VIH in accordance with the amended and restated memorandum and articles of association of VIH. For the avoidance of doubt, in the event that VIH does not effect a VIH Liquidation or instead consummates a business combination with
another entity, the Target Company shall no longer be obligated to issue a Warrant to VIH pursuant to this Section 3.1(a)(ii) and the Warrant (if issued) shall be deemed cancelled; provided, further that upon
entry into a business combination agreement the Warrant shall be deemed non-exercisable and upon consummation of the business combination, shall be deemed cancelled. 

(b) If, prior to the VIH Liquidation, the Target Company consummates any transaction that would be deemed a Sale of the Company (as defined
below) in accordance with Section 3.1(c), the Target Company shall (i) provide VIH with at least five (5) Business Days’ prior written notice of the anticipated consummation of such Sale of the Company, and
shall provide VIH with all reasonably requested information related thereto, and (ii) include as an express provision of such transaction the counterparty’s agreement to issue the Warrant to VIH in accordance with
Section 3.1(a)(ii), subject to the limitations contained therein. For purposes of this Agreement, “Sale of the Company” means, whether in one or a series of transactions, (w) any merger, consolidation
or other business combination in which the Target Company is directly or indirectly combined with (A) a special purpose acquisition company (“SPAC”) or (B) another Person and upon consummation of such transaction described
in this clause (w)(B), the shareholders of the Target Company immediately preceding such transaction would hold less than fifty-one (51%) of the equity interests in the surviving or resulting entity
(whether by voting or number of shares), (x) the sale, lease, transfer, exclusive license or other disposition, in a single transaction or series of related transactions, by the Target Company or any Subsidiary of the Target Company of a majority of
the assets of the Target Company and its Subsidiaries taken as a whole (or assets generating a majority of the revenues or net profits of the Target Company and its Subsidiaries taken as a whole), or the sale or disposition (whether by merger or
otherwise) of one or more Subsidiaries of the Target Company if a majority of the assets of the Target Company and its Subsidiaries taken as a whole (or assets generating a majority of the revenues or net profits of the Target Company and its
Subsidiaries taken as a whole) are held by such Subsidiary or Subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to another wholly-owned Subsidiary of the Target Company, (y) the sale, transfer or
other disposition by the Shareholders or any other equityholder of the Target Company, in a single transaction or series of related transactions, to one Person or group of related Persons, the Target Company’s Equity

  
 3 

 
Interests constituting at least a majority of the fully diluted shares of the Target Company or the Target Company’s Equity Interests that represent at least a majority of the voting power
or economic right of all of the Target Company’s Equity Interests, or any other transaction or series of related transactions of any kind or nature that results in a single party (or group of affiliated parties), acquiring or holding Equity
Interests of the Target Company representing a majority of the outstanding voting power or economic right of the Target Company, or (z) any combination of the transactions in the foregoing clauses (w) through (y). 

(c) Prior to March 5, 2023, unless VIH has otherwise consummated a business combination on or prior to such date, the Target Company shall
not consummate (x) an initial public offering (“IPO”) of its Equity Securities or (y) any merger, consolidation or other business combination directly or indirectly involving a SPAC in which the Target Company is directly
or indirectly a constituent party (“SPAC Transaction”), without the prior written consent of VIH. Subject to the preceding sentence, if (i) the Target Company consummates (A) an IPO of its Target Company Ordinary Shares
pursuant to a registration statement on any recognizable international stock exchange, including the Singapore Exchange, Nasdaq or New York Stock Exchange or (B) a SPAC Transaction, and (ii) VIH has not yet completed the VIH Liquidation by
the time of consummation of such IPO or SPAC Transaction, then the Target Company, at its sole discretion, shall thereafter have the option to pay cash to VIH, in lieu of issuing the Warrant, in an amount equal to the fair market value of the
Warrant on the date that such transaction is consummated. 
 Section 3.2. Default Rate; Fees of Counsel. 

(a) If the Target Company fails to pay the Termination Reimbursement Amount in accordance with Section 3.1(a)(i), a
default interest of five percent (5%) per annum shall accrue on a daily basis from the date the Termination Reimbursement Amount was due and payable pursuant to Section 3.1(a)(i) until all such unpaid amounts have been paid
in full (such interest, the “Default Interest”). 
 (b) The Target Company shall bear, and pay or cause to be paid in full,
within ten (10) calendar days of a written demand by VIH (or its liquidating trust) or VIH Sponsor, all fees, costs and expenses incurred by or on behalf of VIH (or its liquidating trust) or VIH Sponsor (as applicable) in enforcing and
collecting the Termination Reimbursement Amount and/or the Equity Termination Fee, as applicable (including any Default Interest payable under Section 3.2(a)) due and unpaid (or unissued, as applicable), in breach of the
terms of this Agreement, including, without limitation, all fees, costs and expenses of any counsel retained by VIH (or its liquidating trust) or VIH Sponsor (as applicable) for advice, suit, appeal, insolvency or other proceedings related to
enforcement of such breach.  
 Section 3.3. Payments. All payments due under this Agreement shall be paid in full,
without deduction of taxes or other fees which may be imposed by any Governmental Authority or other Person. All payments hereunder shall be in U.S. dollars in immediately available funds. 

ARTICLE IV 

REPRESENTATIONS AND WARRANTIES 

Section 4.1. Representations and Warranties. Each of the Parties hereto represents and warrants to the other Parties that: 

(a) It has duly executed and delivered this Agreement and is fully authorized to enter into and perform this Agreement and every term hereof
and no further consents or approvals are required; 
 (b) It has been represented by legal counsel in the negotiation and joint preparation
of this Agreement, has received advice from legal counsel in connection with this Agreement and is fully aware of this Agreement’s provisions and legal effect; 

  
 4 

 (c) It enters into this Agreement freely, without coercion, and based on its own judgment
and not in reliance upon any representations or promises made by the other Party, apart from those set forth in this Agreement; and 
 (d) It
has the authority, and has obtained all necessary approvals, including but not limited to approval of the Parties’ respective Boards of Directors (or equivalent governing bodies), as necessary, to enter into this Agreement and all the
undertakings, covenants, representations, warranties and other obligations and provisions contained in this Agreement. 
 ARTICLE V

 RELEASE 

Section 5.1. VIH Release. Each of the Target Company, Holdco, Merger Sub, the Shareholders and the Shareholders Representative,
each for itself, and on behalf of their respective Affiliates, and each of their respective equityholders, partners, joint venturers, lenders, administrators, representatives, shareholders (including, without limitation, the Shareholders), parents,
Subsidiaries, officers, directors, attorneys, agents, employees, legatees, devisees, executors, trustees, beneficiaries, insurers, predecessors, successors, heirs and assigns (collectively, the “Target Company Releasing Parties”),
hereby absolutely, forever and fully release and discharge VIH, VIH Sponsor and their respective Affiliates and each of their respective present and former direct and indirect equityholders, directors, managers, officers, employees, predecessors,
partners, shareholders, members, principals, investors, investment managers, joint venturers, administrators, representatives, Affiliates, attorneys, agents, brokers, insurers, parent entities, Subsidiary entities, successors, heirs, and assigns,
and each of them (collectively, the “VIH Released Persons”), from all Claims with respect to, pertaining to, based on, arising out of, resulting from, or relating to the Business Combination Agreement, the Ancillary Documents or the
transactions contemplated by the Business Combination Agreement, including, for the avoidance of doubt, any claims related to the reimbursement of expenses incurred in connection with the termination or negotiation of the Business Combination
Agreement, including, any claims for attorney’s fees and any and all other transaction expenses related thereto (collectively, the “Target Company Released Claims”); provided however, that the foregoing release
not shall apply to any Claims, in each case whether currently known or unknown, relating to (i) any claims that cannot be waived by Law and (ii) any of the VPC Financing Agreements or any other commercial transactions entered into between
any of the Target Company Releasing Parties, on the one hand, and any of VIH, VIH Sponsor or any other VIH Released Persons, on the other hand, unrelated to the Business Combination Agreement (clauses (i) through (ii), the
“Target Company Excluded Matters”); provided, further, that nothing contained herein shall be deemed to release any Party from its obligations under this Agreement (including, without limitation, the Warrant), or
Sections 13.13 (Trust Account Waiver) and Section 13.18 (Shareholders Representative) of the Business Combination Agreement (which provisions shall be deemed to be incorporated herein by reference and shall apply mutatis
mutandis as if set forth at length herein) (the “Surviving BCA Provisions”), and the “Target Company Released Claims” shall be deemed to exclude any Claims with respect to, pertaining to, based on, arising out of,
resulting from, or relating to the Target Company Excluded Matters or any obligations of VIH and/or any other VIH Released Persons under this Agreement (including, without limitation, the Warrant) or the Surviving BCA Provisions. 

Section 5.2. Target Company Release. VIH, for itself, and on behalf of its Affiliates, VIH Sponsor, equityholders, partners, joint
venturers, lenders, administrators, representatives, shareholders, parents, Subsidiaries, officers, directors, attorneys, agents, employees, legatees, devisees, executors, trustees, beneficiaries, insurers, predecessors, successors, heirs and
assigns (collectively, the “VIH Releasing Parties”), hereby absolutely, forever and fully release and discharge the Target Company and its Affiliates and each of its respective present and former direct and indirect equityholders,
directors, officers, employees, predecessors, partners, shareholders, joint venturers, administrators, representatives, affiliates, 

  
 5 

 
attorneys, agents, brokers, insurers, parent entities, Subsidiary entities, successors, heirs, and assigns, and each of them (collectively, the “Target Company Released Persons”
and together with the VIH Released Persons, the “Released Persons”), from all Claims with respect to, pertaining to, based on, arising out of, resulting from, or relating to the Business Combination Agreement, the Ancillary
Documents or the transactions contemplated by the Business Combination Agreement, including, for the avoidance of doubt, any claims related to the reimbursement of expenses incurred in connection with the termination or negotiation of the Business
Combination Agreement, including, any claims for attorney’s fees and any and all other transaction expenses related thereto (but excluding, for all purposes, Claims in respect of the payment and/or issuance of the Termination Reimbursement
Amount and Equity Termination Fee, and the obligations of the Target Company Released Persons in respect thereof) (collectively, the “VIH Released Claims” and together with the Target Company Released Claims, the “Released
Claims”); provided however, that the foregoing release shall not apply to any Claims, in each case whether currently known or unknown, relating to (i) any claims that cannot be waived by Law, (ii) any of the VPC
Financing Agreements (including, for the avoidance of doubt, any Target Company Releasing Parties’ obligations under any of the VPC Financing Agreements) or any other commercial transactions entered into between any of the VIH Releasing
Parties, on the one hand, and any of Holdco, Merger Sub, the Target Company, the Shareholders Representative, the Shareholders and/or any other Target Company Released Persons, on the other hand, unrelated to the Business Combination Agreement
(clauses (i) through (ii), the “VIH Excluded Matters”); provided, further, for the avoidance of doubt, that nothing contained herein shall be deemed to release (x) any Party from its obligations
under this Agreement, the Warrant or the Surviving BCA Provisions, and the “VIH Released Claims” shall be deemed to exclude any Claims with respect to, pertaining to, based on, arising out of, resulting from, or relating to the VIH
Excluded Matters or any obligations of Holdco, Merger Sub, the Target Company, the Shareholders Representative, the Shareholders and/or any other Target Company Released Persons under this Agreement, the Warrant or the Surviving BCA Provisions or
(y) any Party from its obligations under the VPC Financing Agreements, including, without limitation, the VPC Warrant, and the “VIH Released Claims” shall be deemed to exclude any Claims with respect to, pertaining to, based on,
arising out of, resulting from, or relating to or any obligations of any obligations of any Target Company Released Person under the VPC Financing Agreements. 

ARTICLE VI 
 GENERAL
PROVISIONS 
 Section 6.1. Press Release; Required Disclosure. 

(a) The Parties shall issue a press release with respect to the termination of the Business Combination Agreement and Ancillary Documents, in a
form that is mutually agreed upon by the Target Company and VIH. Thereafter, except as otherwise provided in Section 6.1(b), none of VIH, Holdco, the Target Company, Merger Sub, the Shareholders’ Representative or any
of their respective Affiliates shall, make any public announcement or issue any public communication regarding this Agreement or such termination of the Business Combination, or any matter related to the foregoing, without first obtaining the prior
consent of the Target Company or VIH (or following the VIH Liquidation, VIH Sponsor), as applicable (which consent shall not be unreasonably withheld, conditioned or delayed), except if such announcement or other communication is required by
applicable Law or legal process (including pursuant to Securities Laws or the rules of any national securities exchange), in which case VIH (or VIH Sponsor, as applicable) or the Target Company, as applicable, shall use their commercially reasonable
efforts to coordinate such announcement or communication with the other Party, prior to announcement or issuance and allow the other party a reasonable opportunity to comment thereon (which shall be considered by VIH (or VIH Sponsor, as applicable)
or the Target Company, as applicable, in good faith); provided, however, that, notwithstanding anything contained in this Agreement to the contrary, each Party and its Affiliates may make announcements and may provide information
regarding this Agreement and the termination of the Business Combination Agreement to their respective owners, their Affiliates, and its and their respective directors, officers, employees, managers, advisors, direct and indirect investors and
prospective investors without the consent of any other Party. 

  
 6 

 (b) The Parties acknowledge and agree that, notwithstanding anything to the contrary in
Section 6.1(a) of this Agreement or Section 10.11 of the Business Combination Agreement, following the earlier of the Termination Date or the execution of this Agreement by VIH, VIH may issue a Current Report on Form 8-K reporting the execution of this Agreement in the form and timing determined by VIH. 

Section 6.2. Counterparts; Electronic Signatures. This Agreement and any other agreements referred to herein or therein, and any
amendments hereto or thereto, may be executed and delivered (including by facsimile or other electronic transmission) in one or more counterparts, each of which shall constitute an original and need not contain the signature of more than one Party
or party, but all of which taken together shall constitute one and the same agreement. Any counterpart, to the extent signed and delivered by means of a facsimile machine, .pdf or other electronic transmission (including, without limitation,
DocuSign or AdobeSign), shall be treated in all manner and respects as an original contract and shall be considered to have the same binding legal effects as if it were the original signed version thereof delivered in person. At the request of any
Party hereto or party to any such contract, each other Party hereto or party thereto shall re-execute original forms thereof and deliver them to all other Parties hereto or parties thereto. No Party hereto or
party to any such contract shall raise the use of a facsimile machine, .pdf or other electronic transmission (including, without limitation, DocuSign or AdobeSign) to deliver a signature or the fact that any signature or contract was transmitted or
communicated through the use of facsimile machine, .pdf or other electronic transmission (including, without limitation, DocuSign or AdobeSign) as a defense to the formation of a contract and each such Party or party forever waives any such defense

 Section 6.3. Notices. Except as otherwise expressly provided herein, any notice, request, demand or other communication
hereunder shall be sent in writing, addressed as specified below, and shall be deemed given (a) when delivered (i) in person, or (ii) by email, with confirmation of receipt, (b) one (1) Business Day after being sent, if sent
by reputable, internationally recognized overnight courier service or (c) three (3) Business Days after mailing by certified or registered mail, pre-paid and return receipt requested. Notices shall
be addressed to the respective Parties as follows, or to such other address as a Party shall specify to the other parties in accordance with these notice provisions: 

If to the Shareholders, Holdco, Merger Sub or the Target Company, to: 

FinAccel Pte Ltd 
 80 Amoy Street
#03-02 (Attic Floor) 
 Singapore 069899 

Attn: Abhijay Sethia, Matt Mullarkey 

Email: abhijay.sethia@finaccel.co., 

matt.mullarkey@finaccel.co 

with a copy (which shall not constitute notice) to: 

Cooley LLP 
 Ocean Financial
Centre 
 182 Cecil Street 
 #38-01 Frasers Tower 
 Singapore 069547 

Attn:    Rama Padmanabhan, Will Cai, Ferish Patel, David Peinsipp, Matthew Bartus 

Email:  padmanabhan@cooley.com; wcai@cooley.com; fpatel@cooley.com; 

             dpeinsipp@cooley.com; mbartus@cooley.com 

  
 7 

 
			
	If to VIH, to:
	
	VPC Impact Acquisition Holdings II
	Victory Park Capital Advisors, LLC
	150 North Riverside Plaza, Suite 5200
	Chicago, Illinois 60606
	Attn:	  	Scott R. Zemnick
	Email:	  	szemnick@vpcadvisors.com
	
	with a copy (which shall not constitute notice) to:
	
	White & Case LLP
	111 South Wacker Drive, Suite 5100
	Chicago, IL 60606
	Attn:	  	Raymond Bogenrief
	Email:	  	raymond.bogenrief@whitecase.com
	
	and
	
	White & Case LLP
	1221 Avenue of the Americas
	New York, NY 10020
	Attn:	  	James Hu
	Email:	  	james.hu@whitecase.com

 Section 6.4. Governing Law. This Agreement, and any claim, action, suit, investigation or
proceeding of any kind whatsoever, including a counterclaim, cross-claim, or defense, regardless of the legal theory under which such liability or obligation may be sought to be imposed, including statutes of limitations, whether sounding in
contract or tort, or whether at law or in equity, or otherwise under any legal or equitable theory, that may be based upon, arising out of or related to this Agreement, any other agreement contemplated hereby or the negotiation, execution or
performance of this Agreement, such other agreement or the transactions contemplated hereby or thereby, shall be construed in accordance with and governed by the Laws of the State of Delaware, without giving effect to any Law, rule, statute,
procedure, provision or principal (including, without limitation, conflict of laws or choice of laws principals, provisions, procedures, statutes, rules or Laws) that would cause the application of the Laws, rules, statutes, procedures, provisions
or principals of any jurisdiction other than the State of Delaware; provided that, notwithstanding the foregoing, the laws of Cayman Islands shall apply to VIH in respect of the VIH Liquidation in all respects. 

Section 6.5. WAIVER OF JURY TRIAL. THE PARTIES TO THIS AGREEMENT HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVE, TO THE
FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT EACH SUCH PARTY MAY HAVE TO TRIAL BY JURY IN ANY CLAIM, ACTION, SUIT, INVESTIGATION OR PROCEEDING OF ANY KIND OR NATURE ARISING OUT OF OR IN CONNECTION WITH THIS AGREEMENT OR ANY AGREEMENT
CONTEMPLATED HEREBY OR THE TRANSACTIONS CONTEMPLATED HEREBY AND THEREBY, WHETHER BASED ON CONTRACT, TORT OR ANY OTHER LEGAL OR EQUITABLE THEORY. EACH OF THE PARTIES HERETO AGREES AND CONSENTS THAT ANY SUCH CLAIM, ACTION, SUIT, INVESTIGATION OR
PROCEEDING WILL BE DECIDED BY COURT TRIAL WITHOUT A JURY AND THAT THE PARTIES HERETO MAY FILE AN ORIGINAL COUNTERPART OF A COPY OF THIS AGREEMENT WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE PARTIES HERETO TO THE IRREVOCABLE WAIVER OF
SUCH PARTY’S RIGHT TO TRIAL BY JURY. EACH PARTY HERETO (I) CERTIFIES THAT NO 

  
 8 

 
ADVISOR OF ANY OTHER PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (II) ACKNOWLEDGES
THAT IT AND THE OTHER PARTIES HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 

Section 6.6. Submission to Jurisdiction. Any claim, action, suit, investigation or proceeding of any kind whatsoever, including a
counterclaim, cross-claim, or defense, regardless of the legal theory under which such liability or obligation may be sought to be imposed, whether sounding in contract or tort, or whether at law or in equity, or otherwise under any legal or
equitable theory, that may be based upon, arising out of or related to this Agreement or the negotiation, execution or performance of this Agreement or the transactions contemplated hereby brought by any other Party or its successors or assigns
shall be brought and determined only in the Court of Chancery of the State of Delaware in and for New Castle County, Delaware or, if such court shall not have jurisdiction, any federal court located in the State of Delaware or other Delaware state
court, and each of the Parties irrevocably consents and submits to the exclusive jurisdiction of each such court, for itself and with respect to its property, generally and unconditionally, in any such claim, action, suit, proceeding or
investigation, waives any objection it may now or hereafter have to personal jurisdiction, venue or to convenience of forum, agrees that all claims in respect of the claim, action, suit, proceeding or investigation shall be heard and determined only
in any such court, and agrees not to bring any claim, action, suit, proceeding or investigation arising out of or relating to this Agreement or the transactions contemplated hereby in any other court. Each of the Parties agrees not to commence any
claim, action, suit, proceeding or investigation relating thereto except in the courts described above in Delaware, other than actions in any court of competent jurisdiction to enforce any judgment, decree or award rendered by any such court in
Delaware as described herein, and no Party shall file a motion to dismiss any action filed in Delaware consistent with this Section 6.6, on any jurisdictional or venue-related grounds, including the doctrine of forum non
conveniens. The Parties irrevocably agree that venue would be proper in the courts of Delaware described above, and hereby irrevocably waive any objection that any such court is an improper or inconvenient forum for the resolution of such
Action. Nothing herein contained shall be deemed to affect the right of any Party to serve process in any manner permitted by Law or to commence legal proceedings or otherwise proceed against any other Party in any other jurisdiction, in each case,
to enforce judgments obtained in any claim, action, suit, investigation or proceeding brought pursuant to this Section 6.6. 

Section 6.7. Integration; Assignment; Binding Effect. This Agreement (together with the Warrant and the definitions set forth in
the Business Combination Agreement that are referenced herein) constitutes the entire agreement among the Parties with respect to their rights and obligations upon and after the Business Combination Agreement Termination and supersedes all other
prior agreements and understandings, both written and oral, among the Parties with respect to this subject matter. This Agreement may not be assigned by any Party without the prior written consent of VIH (or following the dissolution or liquidation
of VIH, VIH Sponsor) and the Target Company; provided that, following or in connection with the dissolution or liquidation of VIH, this Agreement may be assigned by VIH to the VIH Sponsor without the prior written consent of the Target
Company, so long as VIH Sponsor acknowledges and assumes VIH’s obligations under this Agreement, in a writing signed by VIH Sponsor addressed to the Parties to this Agreement. Any attempted assignment of this Agreement not in accordance with
the terms of this Section 6.7 shall be void. This Agreement shall be binding upon and shall inure to the benefit of the Parties hereto and their respective successors and, subject to the preceding sentence, assigns. 

Section 6.8. Parties in Interest. This Agreement shall be binding upon and inure solely to the benefit of each Party and its
successors and permitted assigns. Each Party hereto acknowledges and agrees that each of the non-party Released Persons are express third party beneficiaries of the releases of such non-party Released Persons contained in Article V and are entitled to enforce rights under such sections to the same extent that such non-party Released Persons could
enforce such rights if they were a party to this 

  
 9 

 
Agreement. Each Party hereto further acknowledges and agrees that VIH Sponsor is an express third party beneficiary to all rights of VIH under this Agreement following the VIH Liquidation. Except
as provided in the preceding two sentences, there are no third-party beneficiaries to this Agreement, and this Agreement is not otherwise intended to and shall not otherwise confer upon any Person other than the Parties hereto and their successors
and permitted assigns any rights or remedies hereunder. 
 Section 6.9. Severability. Whenever possible, each provision of this
Agreement shall be interpreted in such manner as to be effective and valid under applicable Law, but in case any provision in this Agreement shall be held invalid, illegal or unenforceable by a court or other legal authority of competent
jurisdiction in any jurisdiction, such provision shall be modified or deleted, as to such jurisdiction, only to the extent necessary to render the same valid, legal and enforceable, and the validity, legality and enforceability of the remaining
provisions hereof shall not in any way be affected or impaired thereby nor shall the validity, legality or enforceability of such provision be affected thereby in any other jurisdiction. Upon such determination that any term or other provision is
invalid, illegal or incapable of being enforced, the Parties hereto shall substitute for any invalid, illegal or unenforceable provision a suitable and equitable provision that carries out, so far as may be valid, legal and enforceable, the intent
and purpose of such invalid, illegal or unenforceable provision. 
 Section 6.10. Construction; Interpretation. The term
“this Agreement” means this Termination and Fee Agreement together with the Annexes hereto, as the same may from time to time be amended, modified, supplemented or restated in accordance with the terms hereof. The headings set forth in
this Agreement are inserted for convenience only and shall not affect in any way the meaning or interpretation of this Agreement. No Party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing the
provisions hereof, and all provisions of this Agreement shall be construed according to their fair meaning and not strictly for or against any Party. Unless otherwise indicated to the contrary herein by the context or use thereof: (a) the
words, “herein,” “hereto,” “hereof” and words of similar import refer to this Agreement as a whole, including the Annexes, and not to any particular section, subsection, paragraph, subparagraph or clause set forth in
this Agreement; (b) masculine gender shall also include the feminine and neutral genders, and vice versa; (c) words importing the singular shall also include the plural, and vice versa; (d) the words “include,”
“includes” or “including” shall be deemed to be followed by the words “without limitation”; (e) references to “$” or “dollar” or “US$” shall be references to United States dollars;
(f) the word “or” is disjunctive but not necessarily exclusive; (g) the words “writing”, “written” and comparable terms refer to printing, typing and other means of reproducing words (including electronic
media) in a visible form; (h) the word “day” means calendar day unless Business Day is expressly specified; (i) the word “extent” in the phrase “to the extent” means the degree to which a subject or other
thing extends, and such phrase shall not mean simply “if”; (j) all references to Articles, Sections or Annexes are to Articles, Sections or Annexes of this Agreement; and (k) all references to any Law will be to such Law as amended,
supplemented or otherwise modified or re-enacted from time to time. If any action under this Agreement is required to be done or taken on a day that is not a Business Day, then such action shall be required to
be done or taken not on such day but on the first succeeding Business Day thereafter. 
 [Signature Page Follows] 

  
 10 

 IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed and
delivered as of the date first above written. 
  

			
	VIH:
	
	VPC IMPACT ACQUISITION HOLDINGS II
		
	By:	 	 /s/ Gordon Watson

	Name: Gordon Watson
	Title: Co-Chief Executive Officer

 [Signature Page to Termination and Fee Agreement] 

 IN WITNESS WHEREOF, the undersigned have caused this Agreement to be duly executed and
delivered as of the date first above written. 
  

			
	HOLDCO:
	
	AG1 HOLDINGS, LTD.
		
	By:	 	 /s/ Akshay Garg

	Name:	 	Akshay Garg
	Title:	 	Director
	
	MERGER SUB:
	
	AG2 HOLDINGS, LTD.
		
	By:	 	 /s/ Akshay Garg

	Name:	 	Akshay Garg
	Title:	 	Director
	
	TARGET COMPANY:
	
	FINACCEL PTE LTD.
		
	By:	 	 /s/ Akshay Garg

	Name:	 	Akshay Garg
	Title:	 	Director
	
	SHAREHOLDERS REPRESENTATIVE:
		
	By:	 	 /s/ Akshay Garg

	Name:	 	Akshay Garg

 [Signature Page to Termination and Fee Agreement] 

 ANNEX A 

VIH Account Wire InstructionsDocument

Exhibit 4.2

DESCRIPTION OF BLUE FOUNDRY BANCORP’S SECURITIES

As of July 15, 2021, the common stock of Blue Foundry Bancorp (“Blue Foundry”) is registered under Section 12(b) of the Securities Exchange Act of 1934, as amended.

The following description of our common stock, certain provisions of our certificate of incorporation and bylaws and certain provisions of Delaware law is a summary and is qualified in its entirety by reference to our Certificate of Incorporation, Bylaws and the Delaware General Corporation Law (the “DGCL”). Copies of our Certificate of Incorporation and our Bylaws have been filed with the Securities and Exchange Commission (the “SEC”) and are filed as exhibits to Blue Foundry’s Annual Report on Form 10-K filed with the SEC of which this Exhibit is a part.

General

Blue Foundry is authorized to issue 70,000,000 shares of common stock, par value of $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share. Each share of common stock has the same relative rights as, and is identical in all respects to, each other share of common stock.

Voting Rights

The holders of common stock of Blue Foundry have exclusive voting rights in Blue Foundry. They elect Blue Foundry’s board of directors and act on other matters as are required to be presented to them under Delaware law or as are otherwise presented to them by the board of directors. Generally, each holder of common stock is entitled to one vote per share and does not have any right to cumulate votes in the election of directors. Any person who beneficially owns more than 10% of the then-outstanding shares of Blue Foundry Bancorp’s common stock, however, is not entitled or permitted to vote any shares of common stock held in excess of the 10% limit. If Blue Foundry issues shares of preferred stock, holders of the preferred stock may also possess voting rights.

Preemptive Rights 

Holders of the common stock of Blue Foundry are not entitled to preemptive rights with respect to any shares that may be issued. The common stock is not subject to redemption.

Dividends

Blue Foundry may pay dividends on its common stock if, after giving effect to such dividends, it would be able to pay its debts in the usual course of business and its total assets would exceed the sum of its total liabilities plus the amount needed to satisfy the preferential rights upon dissolution of shareholders whose preferential rights on dissolution are superior to those receiving the dividends. However, even if Blue Foundry’s assets are less than the amount necessary to satisfy the requirement set forth above, Blue Foundry may pay dividends from: its net earnings for the fiscal year in which the distribution is made; its net earnings for the preceding fiscal year; or the sum of its net earnings for the preceding eight fiscal quarters. The payment of dividends by Blue Foundry is also subject to limitations that are imposed by applicable regulation, including restrictions on payments of dividends that would reduce Blue Foundry’s assets below the then-adjusted balance of its liquidation account. The holders of common stock of Blue Foundry will be entitled to receive and share equally in dividends as may be declared by our board of directors out of funds legally available therefor. If Blue Foundry issues shares of preferred stock, the holders thereof may have a priority over the holders of the common stock with respect to dividends.

Blue Foundry’s principal assets and sources of income consist of investments in our operating subsidiaries, which are separate and distinct legal entities.

Preferred Stock

None of Blue Foundry’s authorized shares of preferred stock have been issued. Preferred stock may be issued with preferences and designations as our board of directors may from time to time determine. Our board of directors may, without stockholder approval, issue shares of preferred stock with voting, dividend, liquidation and conversion rights that could dilute the voting strength of the holders of the common stock and may assist management in impeding an unfriendly takeover or attempted change in control.

Certain Certificate of Incorporation and Bylaw Provisions Affecting Stock

Blue Foundry’s Certificate of Incorporation and Bylaws contain several provisions that may make Blue Foundry a less attractive target for an acquisition of control by anyone who does not have the support of Blue Foundry’s board of directors. Such provisions include, among other things, a prohibition on any person from voting more than 10% of our outstanding shares of common stock. Furthermore, shares of restricted stock and stock options that we have granted or may grant to employees and directors, stock ownership by our management and directors, shares held by the employee stock ownership plan and other factors may make it more difficult for companies or persons to acquire control of Blue Foundry without the consent of our board of directors. Additionally, our Bylaws provide that we will indemnify our directors and executive officers to the fullest extent permitted by law. The foregoing is qualified in its entirely by reference to Blue Foundry’s Certificate of Incorporation and Bylaws, both of which are on file with the SEC.

Restrictions on Ownership

Under the federal Change in Bank Control Act, a notice must be submitted to the Federal Reserve if any person (including a company), or group acting in concert, seeks to acquire “control” of a bank holding company or bank. An acquisition of “control” can occur upon the acquisition of 10% or more of a class of voting securities of a bank holding company or bank or as otherwise defined by the Federal Reserve. Under the Change in Bank Control Act, the Federal Reserve has 60 days from the filing of a complete notice to act, taking into consideration certain factors, including the financial and managerial resources of the acquirer and the anti-trust effects of the acquisition.

Federal Conversion Regulations

The conversion of Blue Foundry, MHC and Blue Foundry from the mutual holding company form of organization to a fully public stock holding company structure was completed on July 15, 2021. Without the prior written approval of the Federal Reserve, no person may make an offer or announcement of an offer to purchase shares or actually acquire shares of a converted institution or its holding company for a period of three years from the date of the completion of the conversion if, upon the completion of such offer, announcement or acquisition, the person would become the beneficial owner of more than 10% of the outstanding stock of the institution or its holding company. The Federal Reserve has defined “person” to include any individual, group acting in concert, corporation, partnership, association, joint stock company, trust, unincorporated organization or similar company, a syndicate or any other group formed for the purpose of acquiring, holding or disposing of securities of an insured institution. However, offers made exclusively to a bank or its holding company, or to an underwriter or member of a selling group acting on the converting institution’s or its holding company’s behalf for resale to the general public, are excepted. The regulation also provides civil penalties for willful violation or assistance in any such violation of the regulation by any person connected with the management of the converting institution or its holding company or who controls more than 10% of the outstanding shares or voting rights of a converted institution or its holding company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00341-of-00352.parquet"}]]